. "Appendix 20: Respiratory Syncytial Virus." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
Table A20–2 Disease Scenarios for RSV
No. of Cases
% of Cases
Committee HUI Values
Duration (years)
AGE<1
Total Deaths
300
Total Cases
1,000,000
Upper Respiratory
pharyngitis, otitis media
600,000
60.00%
0.90
0.0192 (7 days)
Bronchiolitis/pneumonia
outpatient only
340,000
34.00%
0.75
0.0274 (10 days)
Bronchiolitis/pneumonia
60,000
6.00%
inpatient
0.50
0.0192 (7 days)
outpatient
0.75
0.0082 (3 days)
AGE 1–4
Total Deaths (from acute infection)
200
Total Cases
2,000,000
Upper Respiratory
pharyngitis, otitis media
1,200,000
60.00%
0.90
0.0192 (7 days)
Bronchiolitis/pneumonia
outpatient only
760,000
38.00%
0.75
0.0274 (10 days)
Bronchiolitis/pneumonia
40,000
2.00%
inpatient
0.50
0.0192 (7 days)
outpatient
0.75
0.0082 (3 days)
AGE 5+
Total Deaths (from acute infection)
20
Total Cases
2,000,000
Upper Respiratory
pharyngitis, otitis media
1,600,000
80.00%
0.90
0.0192 (7 days)
Bronchiolitis/pneumonia
outpatient only
396,000
19.80%
0.75
0.0274 (10 days)
Bronchiolitis/pneumonia
4,000
0.20%
inpatient
0.50
0.0192 (7 days)
outpatient
0.75
0.0082 (7 days)
VACCINE PROGRAM CONSIDERATIONS
Target Population
For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is all adolescent girls (age 12 years) and all infants. For this example, the committee included adolescent girls in order to induce immunity that would protect the neonate. Infants are immunized to protect against disease after 1 year of age. It was assumed that 50% of adolescent females and 90% of infants would utilize the vaccine.
